ArticleACS nano medicine2026
Nonenzymatic Detection of SARS-CoV‑2 RNA Using DNA Nanoswitches.
Article in ACS nano medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ligation-assisted target recycling for DNA nanoswitch biosensors.bioRxiv : the preprint server for biology · 2026Article
- Resolving altered base-pairing of RNA modifications with DNA nanoswitches.Nucleic acids research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The emergence of a highly contagious coronavirus in 2019 led to an unprecedented need for large-scale diagnostic testing. The associated challenges, including reagent shortages, cost, deployment delays, and turnaround time, have all highlighted the need for an alternative suite of low-cost tests. Here, we demonstrate a test for SARS-CoV-2 RNA that provides direct detection of viral RNA and eliminates the need for costly enzymes. We employ DNA nanoswitches that respond to segments of the viral RNA by a change in shape that can be read by gel electrophoresis. A multitargeting approach samples 120 different viral regions to improve the limit of detection and provide robust detection of viral variants. We applied our approach to a cohort of clinical samples, positively identifying a subset of samples with high viral loads. Since our method directly detects multiple regions of viral RNA without amplification, it eliminates the risk of amplicon contamination and renders the method less susceptible to false positives. This tool can benefit diagnostic options for COVID-19 and future emerging outbreaks, providing a third option between amplification-based RNA detection and protein antigen detection. Ultimately, we believe that this tool can be adapted both for low-resource onsite testing as well as for monitoring viral loads in recovering patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.